CATELLA-CARD-AND-PAYMEN
The Capitol Visa Infinite Card is the first card that combines a private banking service with access to an extensive and tailored selection of exclusive lifestyle benefits, privileges and experiences, with the unique opportunity to create a personal jewellery companion card.
Capitol Visa Infinite provides the cardholder with instant access to an unparalleled suite of comprehensive insurance; airport lounges worldwide; exclusive cultural, sporting and fashion events; and the Visa events and experiences programme and Visa Luxury Hotel Collection.
“We have worked extensively with Catella Bank to construct a unique product that addresses the need of their top private banking customers”, says Jean-Marie de Crayencour, Country Manager BeLux at Visa Europe.
The card also offers the unique choice for the client to tailor their card experience in accordance with their lifestyle. For example, an extensive international traveller can choose a bespoke private travel planner service, an all-inclusive Priority Pass membership and extensive insurances.
Together with Rosan Diamond, cardholders have the unique opportunity to create a personal jewellery companion card with a design of their choice. Rosan Diamond Studio was founded in 2000 and is to date the only card producer to create gold cards embellished with precious stones (including diamonds, sapphires, rubies and pearls) and decorated with fine engravings.
“This is the first card that truly combines a private banking service with access to exclusive lifestyle experiences, tailored to match the specific needs of the international private banking clientele. Whatever those needs may be, cardholders can call upon the assistance of their personal concierge, 24/7/365, wherever in the world they may be. On top of this, with a customised spending limit and unmatched card acceptance, the cardholder will never have to let an opportunity slip them by,” says Dawid Feter, Director Bank Solutions at Catella Bank.
Catella Bank S.A. provides turn-key cards and payment solutions. Catella operates as a card issuing and card acquiring bank and has been a Principal Member of Visa International since 1991. Operations are conducted from Luxembourg, and the client base consists of the high net worth and ultra-high net worth clientele of more than 100 private banks. Catella is part of Catella group, an independent financial advisor and asset manager with operations in 12 European countries and some 450 employees. Read more at www.catella.com .
Visa Europe is a payments technology business owned and operated by member banks and other payment service providers from 37 countries across Europe. Visa Europe works at the forefront of technology to create the services and infrastructure which enable millions of European consumers, businesses and governments to make electronic payments. Its members are responsible for issuing cards, signing up retailers and deciding cardholder and retailer fees.There are 500m Visa cards in Europe, while €1 in every €6.50 spent in Europe is on a Visa card. Read more at www.visaeurope.com .
Contact:
Catella - Card and Payment Services
Dawid Feter
Director,
Bank Solutions
+352 691 754 808
dawid.feter@catella.lu
or
Jonathan
Reddin
Head of Cards and Payment Solutions
+352 691 751 204
jonathan.reddin@catella.lu
or
Press
contact:
Ann Charlotte Svensson
Head of Communications
+46
8 463 32 55, +46 72 510 11 61
anncharlotte.svensson@catella.se
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 08:00:00 CEST | Press release
- Streamlining operations and reducing risk in asset integrity management – Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 08:00:00 CEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum